Tolerability, Gut Effects, and Pharmacokinetics of Methylnaltrexone Following Repeated Intravenous Administration in Humans
- 1 May 2005
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 45 (5), 538-546
- https://doi.org/10.1177/0091270004273491
Abstract
Previous studies have shown that a single dose of methylnaltrexone, a unique peripheral opioid antagonist, reverses opioid-induced gut hypomotility in humans. Because repeated drug doses are likely to be needed to treat patients with opioid-induced or postsurgical bowel dysfunction, the authors have now examined the safety, pharmacological activity, and pharmacokinetics of a multiple-dose regimen of methylnaltrexone, administered as 12 consecutive intravenous doses (0.3 mg/kg every 6 hours) in 12 healthy subjects. Steady state was achieved rapidly, and after repeated dosing for 3 days, methylnaltrexone decreased oral-cecal transit time from a pretreatment baseline value of 101.3 +/- 29.4 min (mean +/- SD) to 82.5 +/- 20.7 min. Maximum observed plasma concentrations, measured 5 minutes postdose, were 538 +/- 237 and 675 +/- 180 ng/mL after doses 1 and 2, respectively. Based on 6-hour sampling periods, the plasma half-life, 2.5 +/- 0.5 and 2.9 +/- 0.9 hours following the 1st and 12th doses, respectively, was unchanged at steady state. There was essentially no accumulation of methylnaltrexone, based on the ratio of AUC values after doses 12 and 1. This study showed that repeated administration of intravenous methylnaltrexone is well tolerated in humans, with no significant adverse events or changes in opioid subjective ratings and no clinically noteworthy alterations in pharmacokinetics. The observation of a significant reduction in the gut transit time after repeated administration of methylnaltrexone to these opioid-naive volunteers suggests that endogenous opioids modulate human gut motility.Keywords
This publication has 34 references indexed in Scilit:
- Opioid Antagonists: A Review of Their Role in Palliative Care, Focusing on Use in Opioid-Related ConstipationJournal of Pain and Symptom Management, 2002
- Antagonism of gastrointestinal opioid effectsRegional Anesthesia & Pain Medicine, 2000
- Methylnaltrexone: Investigation of clinical applicationsDrug Development Research, 2000
- Gastric effects of methylnaltrexone on μ, κ and δ opioid agonists induced brainstem unitary responsesNeuropharmacology, 1999
- Unrecognized constipation in patients with advanced cancer: A recipe for therapeutic disasterJournal of Pain and Symptom Management, 1992
- The current status of opioid research on gastrointestinal motilityLife Sciences, 1989
- Oral naloxone antagonizes loperamide-induced delay of orocecal transitDigestive Diseases and Sciences, 1987
- Interpretation of the breath hydrogen profile obtained after ingesting a solid meal containing unabsorbable carbohydrate.Gut, 1985
- Effect of loperamide and naloxone on mouth-to-caecum transit time evaluated by lactulose hydrogen breath test.Gut, 1985
- The Central and Peripheral Influences of Opioids on Gastrointestinal PropulsionAnnual Review of Pharmacology and Toxicology, 1985